JP2016514729A - 2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン、その製造方法及びその用途 - Google Patents
2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン、その製造方法及びその用途 Download PDFInfo
- Publication number
- JP2016514729A JP2016514729A JP2016504473A JP2016504473A JP2016514729A JP 2016514729 A JP2016514729 A JP 2016514729A JP 2016504473 A JP2016504473 A JP 2016504473A JP 2016504473 A JP2016504473 A JP 2016504473A JP 2016514729 A JP2016514729 A JP 2016514729A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction
- solution
- added
- androst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 162
- 238000006243 chemical reaction Methods 0.000 claims description 98
- 210000004027 cell Anatomy 0.000 claims description 14
- 210000002569 neuron Anatomy 0.000 claims description 14
- LYFPAZBMEUSVNA-FZFXZXLVSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 LYFPAZBMEUSVNA-FZFXZXLVSA-N 0.000 claims description 12
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 12
- 208000005400 Synovial Cyst Diseases 0.000 claims description 12
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 239000003223 protective agent Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000001537 neural effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 15
- 239000000243 solution Substances 0.000 description 80
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000007787 solid Substances 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 230000007935 neutral effect Effects 0.000 description 25
- 238000003756 stirring Methods 0.000 description 24
- 239000012065 filter cake Substances 0.000 description 22
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 230000002490 cerebral effect Effects 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 12
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 11
- 235000019253 formic acid Nutrition 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 238000000967 suction filtration Methods 0.000 description 11
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000013065 commercial product Substances 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 210000001328 optic nerve Anatomy 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000005252 bulbus oculi Anatomy 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000016273 neuron death Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003810 Jones reagent Substances 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 208000032253 retinal ischemia Diseases 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- -1 choline ester Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000004693 neuron damage Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical class C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 150000001647 brassinosteroids Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本出願は、2013年3月28日出願の中国特許出願第201310104162.5号の優先権利益を主張し、その開示の全体がここに参考として組み込まれる。
(技術分野)
本発明は、ポリヒドロキシステロンに関し、具体的に、2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン、その製造方法及び医学的使用に関する。
式(I):
の構造式で示される新規ポリヒドロキシステロン系物質である2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン(以下、本明細書で互換的に使われる「YC−10」、「化合物(I)」、「化合物」と称することもある)を提供する。
化合物Iの製造実施例1は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例2は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例3は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例4は、下記の工程(1)〜(6)を含む。
化合物Iの製造実施例5は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例6は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例7は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例8は、下記の工程(1)〜(7)を含む。
化合物Iの製造実施例9は、下記の工程(1)〜(7)を含む。
(1)細胞播種、投与処理
対数増殖期のLN18細胞及びDBTRG−50MG細胞を完全培地で細胞懸濁液に調製し、1ウェルあたり100μl、3×104/mlの密度で96ウェル培養プレートに播種した。12時間後、細胞の培養プレート表面への完全付着が見られ、その後、YC−10の最終濃度がそれぞれ250μM、500μM、1000μMになるようにYC−10を加えた。ここで、各濃度群はぞれぞれ5つのウェルを有する。
24時間培養した後、1ウェルごとにMTT10μl(5mg/ml)を加え、続いて4時間培養した。この時、顕微鏡検査で生細胞内に形成される青紫色の粒状ホルマザン結晶が観察された。
上澄みを注意深く取り除いた後、DMSOを100μl/ウェルで加えて結晶を溶解させ、ミニ発振器で5分間振動させた後、酵素免疫測定装置により波長570nmで各ウェルの光学濃度(OD値)を測定した。
YC−10の神経保護作用の有無及び臨床薬への開発可能性を検討するために、YC−10の毒性及び薬効に対して様々なインビトロ・インビボ研究を行った。研究結果によると、大量のYC−10(250mg/kg)を投与したマウスが、投与後14日以内に明らかな異常は見られなかった。インビトロ培養した初代小脳顆粒ニューロンのグルタミン酸モデル及び低カリウムモデルに対する研究結果によると、YC−10は小脳顆粒ニューロンの生存に対して明らかな保護作用を持つことが見られた。視神経損傷及び網膜虚血の動物モデルに対する研究結果によると、視神経軸索損傷及び網膜虚血の場合、YC−10は視神経節細胞の生存に対して明らかな保護作用を持つことが見られる。以上の研究結果から、YC−10は明らかな毒性及び副作用を有さず、神経保護作用を持つことが分かった。
(最大耐量試験)
40%のヒドロキシプロピルシクロデキストリンを用いて濃度25mg/mlのYC−10注射液を調製した後、注射液を30匹(雄雌半々)の体重18〜22gKMマウスに対して尾静脈注射(0.1ml/10g)を行った。
(2.1)YC−10のグルタミン酸誘発小脳顆粒ニューロン損傷に対する保護作用
インビトロ培養8日目のラット小脳顆粒ニューロンを投与群とモデル群に分け、投与群にMK801又は異なる濃度のYC−10をあらかじめ与え、30分間予備培養した。その後、モデル群及びすべての投与群にそれぞれMg2+フリーLocke緩衝液を与えるとともに、最終濃度100μMのグルタミン酸、10μMのグリシン、及び対応濃度の薬物を与えた。各群を37℃の培養器で30分間培養した後、一般的な培地に置き換え、続いて24時間培養した後、FDA染色を行った。
インビトロ培養8日目のラット小脳顆粒ニューロンを投与群とモデル群に分け、投与群に異なる濃度のYC−10をあらかじめ与え、30分間予備培養した。その後、モデル群及びすべての投与群に5K(すなわち、5mMKCl)のBME培地(対照群:25K)を与えるとともに、対応濃度のYC−10を与えた。各群を37℃の培養器で培養し続け、24時間培養した後、FDA染色を行った。
10%の抱水クロラールでラットに麻酔をかけた後、手術20分前にYC−10(20mg/kg)又は溶媒を尾静脈投与した。その後、目に局部麻酔をかけ、角膜鋏刀及びマイクロ鉗子を用いて角膜縁に沿って結膜を切り離した。外直筋を鈍的剥離して視神経を十分露出させ、その後、クロスアクション鉗子により眼球後部約2mm部位における視神経を締め付けてから5秒後、クロスアクション鉗子を外した。手術した後、感染を防止するために抗生物質眼軟膏を塗布した。手術後2時間、2日目、3日目に薬物を再び投与し、7日後眼球を取り出して病理学検査を行った。
10%の抱水クロラールでラットに麻酔をかけた後、目に局部麻酔をかけた。灌流装置を灌流液面からラット眼球水平面までの距離が176cm(約130mmHgの眼内圧を増加可能)になるように取り付けた後、管口に接続される30G1/2針を眼球前房に注意深く挿入した。この時、眼球が明らかに白色になると、虚血開始時間を記録した。1時間後、針を迅速に抜き出し、抗生物質点眼薬で処理した後、ラットを飼育箱に戻して飼育した。モデリング20分前に溶媒群及びYC−10群(20mg/kg)に薬物を尾静脈投与し、モデリング完了後2時間、2日目、3日目に薬物を再び尾静脈投与した。モデリング7日後、眼球を取り出して病理学検査を行った。
Claims (8)
- 式(I):
の構造式で示される化合物2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン。 - 治療有効量の請求項1に記載の化合物と、薬学的に許容される担体とを含む医薬組成物。
- 治療有効量の請求項1に記載の化合物と、他の神経細胞保護剤とを含む医薬組成物。
- 前記他の神経細胞保護剤は視神経節細胞保護剤である、請求項3に記載の医薬組成物。
- 治療的有効量の請求項1に記載の化合物と、他の抗腫瘍剤とを含む医薬組成物。
- 神経細胞保護剤の製造における請求項1に記載の化合物の使用。
- 抗腫瘍剤の製造における請求項1に記載の化合物の使用。
- 請求項1に記載の化合物の製造方法であって、
アンドロスタ−5−エン−3−オールを原料とし、反応により化合物3β−p−トルエンスルフォニルオキシ−5α−ヒドロキシ−アンドロスタ−6−オンを調製し、脱離反応により化合物5α−ヒドロキシ−アンドロスタ−2−エン−6−オンを調製し、さらに2−位二重結合における酸化、加水分解反応により前記式(I)の化合物を得る、製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310104162.5A CN104072564B (zh) | 2013-03-28 | 2013-03-28 | 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 |
CN201310104162.5 | 2013-03-28 | ||
PCT/CN2014/074318 WO2014154179A1 (zh) | 2013-03-28 | 2014-03-28 | 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016514729A true JP2016514729A (ja) | 2016-05-23 |
JP6106328B2 JP6106328B2 (ja) | 2017-03-29 |
Family
ID=51594205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016504473A Expired - Fee Related JP6106328B2 (ja) | 2013-03-28 | 2014-03-28 | 2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン、その製造方法及びその用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9428539B2 (ja) |
EP (1) | EP2980096B1 (ja) |
JP (1) | JP6106328B2 (ja) |
KR (1) | KR101771192B1 (ja) |
CN (2) | CN104072564B (ja) |
AU (1) | AU2014243510B2 (ja) |
CA (1) | CA2908088C (ja) |
ES (1) | ES2691530T3 (ja) |
IL (1) | IL241768B (ja) |
PT (1) | PT2980096T (ja) |
RU (1) | RU2629929C2 (ja) |
SG (1) | SG11201507877QA (ja) |
TW (1) | TWI504396B (ja) |
WO (1) | WO2014154179A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104561218B (zh) * | 2014-11-09 | 2019-01-11 | 浙江仙居君业药业有限公司 | 一种利用赤霉菌制备3β,7α,15α-三羟基雄甾-5-烯-17-酮的方法 |
CN109985048B (zh) * | 2017-12-29 | 2021-06-29 | 广州市赛普特医药科技股份有限公司 | 2β,3α,5α-三羟基雄甾-6-酮用于炎症反应的治疗 |
CN109985046B (zh) * | 2017-12-29 | 2021-07-27 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇用于炎症介导的视神经病变的治疗 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127465A2 (en) * | 2010-04-09 | 2011-10-13 | The Research Foundation Of The State University Of New York | Ship inhibitors and uses thereof |
WO2012003802A1 (zh) * | 2010-07-09 | 2012-01-12 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
OA11850A (en) * | 1999-03-23 | 2006-03-06 | Hollis Eden Pharmaceuticals | Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone. |
WO2006002907A1 (en) | 2004-06-29 | 2006-01-12 | Jadolabs Gmbh | Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
CN100355809C (zh) | 2004-12-27 | 2007-12-19 | 上海杰事杰新材料股份有限公司 | 一种应用于汽车、摩托车的尼龙燃油箱及其制备方法 |
CN102482315A (zh) * | 2009-07-29 | 2012-05-30 | 芝加哥大学 | 肝x受体激动剂 |
FR2967914A1 (fr) * | 2010-11-29 | 2012-06-01 | Centre Nat Rech Scient | Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques |
-
2013
- 2013-03-28 CN CN201310104162.5A patent/CN104072564B/zh active Active
-
2014
- 2014-03-28 CN CN201480017073.XA patent/CN105189528B/zh active Active
- 2014-03-28 KR KR1020157031029A patent/KR101771192B1/ko active IP Right Grant
- 2014-03-28 RU RU2015141335A patent/RU2629929C2/ru not_active IP Right Cessation
- 2014-03-28 EP EP14774834.7A patent/EP2980096B1/en active Active
- 2014-03-28 CA CA2908088A patent/CA2908088C/en not_active Expired - Fee Related
- 2014-03-28 AU AU2014243510A patent/AU2014243510B2/en not_active Ceased
- 2014-03-28 JP JP2016504473A patent/JP6106328B2/ja not_active Expired - Fee Related
- 2014-03-28 ES ES14774834.7T patent/ES2691530T3/es active Active
- 2014-03-28 TW TW103111715A patent/TWI504396B/zh not_active IP Right Cessation
- 2014-03-28 WO PCT/CN2014/074318 patent/WO2014154179A1/zh active Application Filing
- 2014-03-28 PT PT14774834T patent/PT2980096T/pt unknown
- 2014-03-28 SG SG11201507877QA patent/SG11201507877QA/en unknown
- 2014-03-28 US US14/780,464 patent/US9428539B2/en active Active
-
2015
- 2015-09-21 IL IL241768A patent/IL241768B/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127465A2 (en) * | 2010-04-09 | 2011-10-13 | The Research Foundation Of The State University Of New York | Ship inhibitors and uses thereof |
WO2012003802A1 (zh) * | 2010-07-09 | 2012-01-12 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104072564A (zh) | 2014-10-01 |
WO2014154179A1 (zh) | 2014-10-02 |
PT2980096T (pt) | 2018-11-20 |
CA2908088A1 (en) | 2014-10-02 |
AU2014243510B2 (en) | 2016-08-04 |
US20160039862A1 (en) | 2016-02-11 |
CA2908088C (en) | 2017-02-07 |
CN105189528B (zh) | 2017-04-12 |
EP2980096A4 (en) | 2016-11-16 |
TW201436796A (zh) | 2014-10-01 |
US9428539B2 (en) | 2016-08-30 |
CN104072564B (zh) | 2016-08-17 |
EP2980096A1 (en) | 2016-02-03 |
KR101771192B1 (ko) | 2017-08-24 |
IL241768B (en) | 2019-07-31 |
ES2691530T3 (es) | 2018-11-27 |
EP2980096B1 (en) | 2018-08-15 |
CN105189528A (zh) | 2015-12-23 |
JP6106328B2 (ja) | 2017-03-29 |
KR20160021083A (ko) | 2016-02-24 |
RU2015141335A (ru) | 2017-05-16 |
SG11201507877QA (en) | 2015-10-29 |
TWI504396B (zh) | 2015-10-21 |
AU2014243510A1 (en) | 2015-10-15 |
RU2629929C2 (ru) | 2017-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1990475B (zh) | 取代苯并异硒唑酮类化合物及其用途 | |
US10370364B1 (en) | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | |
JP6106328B2 (ja) | 2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン、その製造方法及びその用途 | |
WO2019129249A1 (zh) | 含三萜类化合物的药物组合物及其用途 | |
JP5350630B2 (ja) | 3,5−セコ−4−ノルコレスタンの新規な誘導体及びその使用 | |
CN101074189B (zh) | 苯乙烯酸衍生物及其在制备血管靶向剂药物中的应用 | |
WO2023025241A1 (zh) | 一种阿比特龙前体化合物及其制备方法和应用 | |
CA2557942A1 (fr) | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique | |
JP2002533323A (ja) | メラトニン誘導体とこの誘導体を含む薬剤 | |
CN107759553A (zh) | 新型类黄酮化合物及其用途 | |
CN114072381A (zh) | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 | |
JP2017095419A (ja) | トリアリールメタン組成物,眼膜染色のための染色組成物 | |
WO2019184919A1 (zh) | 一种含有金刚烷的化合物及其在治疗癌症中的用途 | |
EP1674101B1 (fr) | Dérivés cinnamates de benzo [b]pyrano[3,2-h]acridin-7-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
DE60305520T2 (de) | 2" oxo-voruscharin und derivaten | |
WO2015180549A1 (zh) | L-丙氨酸-(14-冬凌草甲素)酯三氟乙酸盐的i型结晶及制备方法 | |
WO2002008229A1 (fr) | DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO [4,5-β] INDOLE-1-CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
CN1939905A (zh) | 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途 | |
JP2017095439A (ja) | トリアリールメタン組成物,眼膜染色のための染色組成物 | |
CN115232036A (zh) | 一种二苯乙烯多酚牛磺酸酯、制备方法及其用途 | |
WO2021016954A1 (zh) | 3-乙酰基-5-羟基-b-降胆甾醇-6-(n-甲基)缩氨硫腙、制备方法及其用途 | |
TW202245793A (zh) | 3-羥基-5-孕烷-20-酮衍生物的晶型及其製備方法和用途 | |
JP5476650B2 (ja) | 新規dif−1誘導体 | |
PT1572715E (pt) | Compostos de esteróides com actividade anti-tumor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170303 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6106328 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |